NASDAQ · BWAY
Healthcare · Medical - Devices
$13.53
Up+$0.08 (+0.59%)
Updated Sep 19, 2026, 1:25 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
BWAY closed at $13.53 after 19 trading sessions, down 8.21% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $13.425 | $13.70 | $13.15 | $13.53 | 32.57K |
| Sep 16, 2026 | $13.41 | $13.63 | $13.27 | $13.46 | 88.88K |
| Sep 15, 2026 | $13.50 | $13.50 | $13.13 | $13.46 | 123.25K |
| Sep 14, 2026 | $13.51 | $13.835 | $13.3007 | $13.63 | 113.15K |
| Sep 11, 2026 | $14.10 | $14.115 | $13.68 | $13.93 | 68.03K |
| Sep 10, 2026 | $14.12 | $14.175 | $13.86 | $13.91 | 137.3K |
| Sep 9, 2026 | $14.11 | $14.465 | $14.10 | $14.41 | 129K |
| Sep 8, 2026 | $14.01 | $14.48 | $14.00 | $14.16 | 75.87K |
| Sep 4, 2026 | $14.55 | $14.55 | $14.06 | $14.15 | 49.63K |
| Sep 3, 2026 | $14.41 | $14.68 | $14.30 | $14.51 | 59.85K |
| Sep 2, 2026 | $14.34 | $14.78 | $14.08 | $14.28 | 86.47K |
| Sep 1, 2026 | $14.52 | $14.585 | $14.18 | $14.27 | 67.13K |
| Aug 31, 2026 | $14.42 | $14.67 | $14.19 | $14.52 | 80.93K |
| Aug 28, 2026 | $14.55 | $14.67 | $14.09 | $14.30 | 53.37K |
| Aug 27, 2026 | $14.61 | $14.61 | $14.15 | $14.40 | 96.59K |
| Aug 26, 2026 | $14.43 | $14.585 | $14.02 | $14.30 | 74.22K |
| Aug 25, 2026 | $14.32 | $14.62 | $14.215 | $14.43 | 56.6K |
| Aug 24, 2026 | $14.53 | $14.53 | $14.10 | $14.19 | 97.71K |
| Aug 21, 2026 | $14.85 | $15.16 | $14.68 | $14.74 | 47.35K |
The latest Smart Investors Daily articles mentioning BWAY.
BWAY research
Company profile and research snapshot.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2020 | Raymond James | Outperform | — |
| Mar 24, 2020 | Cantor Fitzgerald | Overweight | — |
| Mar 24, 2020 | Raymond James | Outperform | — |
| Nov 26, 2019 | Raymond James | Outperform | — |
| May 13, 2019 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
On August 12, BrainsWay Ltd. (NASDAQ:BWAY) reported second-quarter 2026 results that make the neurostimulation company look less like a niche medtech story and more like a genuine growth compounder. Revenue climbed 35% year over year to a record $17.1 million, and adjusted EBITDA more than doubled to $3.5 million. The company shipped 125 Deep TMS […]
Benzinga · Sep 10, 2026
BTIG analyst Sam Eiber reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $20 price target.
Yahoo · Sep 9, 2026
Investors need to pay close attention to BWAY stock based on the movements in the options market lately.
Benzinga · Sep 8, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $19 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BWAY.
